{
  "id": 8206626,
  "title": "KeyBanc initiates NeuroPace stock coverage with overweight rating",
  "url": "https://urgent.news/2026/09/18/keybanc-initiates-neuropace-stock-coverage-with-overweight-rating",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-18T08:04:45.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/keybanc-initiates-neuropace-stock-coverage-with-overweight-rating-93CH-4906796"
  },
  "original_language": "en",
  "account": "KeyBanc has initiated coverage on NeuroPace Inc (NASDAQ:NPCE), assigning an overweight rating and setting a price target of $18.00. The current stock price is $14.15, indicating a potential upside of 27% from the analyst's target. The firm is optimistic about NeuroPace's commercialization of a unique approach to treat drug-resistant epilepsy. Their core product, the RNS System, is a closed-loop neuromodulation device implanted during an inpatient hospital stay. This system monitors brain activity and delivers electrical stimulation to prevent severe seizures. KeyBanc believes the RNS System's responsive nature and ability to record brain activity data differentiate it from competitors. The company anticipates reaching sustained profitability by the end of 2027, supported by robust revenue growth of 33% over the past year and gross profit margins of 77%. While three analysts have raised their earnings estimates for the upcoming period, InvestingPro notes the stock may be slightly overvalued based on its fair value analysis. Investors can access a more detailed Pro Research Report for further insights. NeuroPace's latest quarterly results surpassed expectations, with an adjusted loss of $0.18 per share and revenue up 17% year-over-year to $22.83 million. Management raised full-year guidance despite regulatory uncertainties. Cantor Fitzgerald upgraded their rating to Overweight with a $21.00 price target, citing commercial momentum and a strong product pipeline, particularly the ECoG Assistant launched in Q2 2026. Investors remain focused on the company's ongoing losses and the uncertainty surrounding its idiopathic generalized epilepsy program.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}